Individualized recombinant human thrombomodulin (ART-123) administration in sepsis patients based on predicted phenotypes
Main Authors: | Daisuke Hasegawa, Osamu Nishida |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2019-06-01
|
Series: | Critical Care |
Online Access: | http://link.springer.com/article/10.1186/s13054-019-2521-7 |
Similar Items
-
Age-related differences in the survival benefit of the administration of antithrombin, recombinant human thrombomodulin, or their combination in sepsis
by: Takeshi Wada, et al.
Published: (2022-06-01) -
Web-based application for predicting the potential target phenotype for recombinant human thrombomodulin therapy in patients with sepsis: analysis of three multicentre registries
by: Tadahiro Goto, et al.
Published: (2022-05-01) -
Protective Role of Recombinant Human Thrombomodulin in Diabetes Mellitus
by: Yuko Okano, et al.
Published: (2021-08-01) -
Effects of recombinant human soluble thrombomodulin on neutrophil extracellular traps in the kidney of a mouse model of endotoxin shock
by: Tatsuhiko Harada, et al.
Published: (2023-08-01) -
Recombinant human soluble thrombomodulin improves mortality in patients with sepsis especially for severe coagulopathy: a retrospective study
by: Takahiro Kato, et al.
Published: (2018-08-01)